{"DataElement":{"publicId":"3235532","version":"1","preferredName":"Pneumococcal Polyvalent Vaccine Analysis Type","preferredDefinition":"A description of the pneumococcal polyvalent vaccine type.","longName":"3235523v1.0:3235525v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"3235523","version":"1","preferredName":"Pneumococcal Polyvalent Vaccine Analysis","preferredDefinition":"An polyvalent vaccine used to prevent infection by the bacterium Streptococcus pneumoniae. Pneumococcal polyvalent vaccine contains highly purified capsular antigens from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae to ensure cross-protection. Following vaccination, protective capsular type-specific antibody levels typically develop by the third week; serotype-specific antibody levels generally decline after 5-10 years._Examination and interpretation; the process of identifying an issue to be understood and addressed, modelling the issue, investigating the model results, interpreting the results, and possibly making a recommendation. The concept also refers to the examination and study of a whole in terms of the parts composing it.","longName":"3235521v1.0:2261838v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"3235521","version":"1","preferredName":"Pneumococcal Polyvalent Vaccine","preferredDefinition":"An polyvalent vaccine used to prevent infection by the bacterium Streptococcus pneumoniae. Pneumococcal polyvalent vaccine contains highly purified capsular antigens from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae to ensure cross-protection. Following vaccination, protective capsular type-specific antibody levels typically develop by the third week; serotype-specific antibody levels generally decline after 5-10 years.","longName":"C1643","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pneumococcal Polyvalent Vaccine","conceptCode":"C1643","definition":"An polyvalent vaccine used to prevent infection by the bacterium Streptococcus pneumoniae. Pneumococcal polyvalent vaccine contains highly purified capsular antigens from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae to ensure cross-protection. Following vaccination, protective capsular type-specific antibody levels typically develop by the third week; serotype-specific antibody levels generally decline after 5-10 years.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A32B237B-1AC3-0954-E040-BB89AD430712","latestVersionIndicator":"Yes","beginDate":"2011-05-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-13","modifiedBy":"ONEDATA","dateModified":"2011-05-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2261838","version":"1","preferredName":"Analysis","preferredDefinition":"Analysis; examination and interpretation.","longName":"C25391","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Analysis","conceptCode":"C25391","definition":"Examination and interpretation; the process of identifying an issue to be understood and addressed, modelling the issue, investigating the model results, interpreting the results, and possibly making a recommendation. The concept also refers to the examination and study of a whole in terms of the parts composing it.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FBB87D79-96F9-0549-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-13","modifiedBy":"ONEDATA","dateModified":"2005-07-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A32B237B-1AD1-0954-E040-BB89AD430712","latestVersionIndicator":"Yes","beginDate":"2011-05-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-13","modifiedBy":"KUMMEROA","dateModified":"2021-03-30","changeDescription":". 2021-3-30 ak OK to release per WZ.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3235525","version":"1","preferredName":"Pneumococcal Polyvalent Vaccine Type","preferredDefinition":"An polyvalent vaccine used to prevent infection by the bacterium Streptococcus pneumoniae. Pneumococcal polyvalent vaccine contains highly purified capsular antigens from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae to ensure cross-protection. Following vaccination, protective capsular type-specific antibody levels typically develop by the third week; serotype-specific antibody levels generally decline after 5-10 years._Type; a subdivision of a particular kind of thing.","longName":"3235525v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Conjugated pneumococcal polysaccharide","valueDescription":"Conjugate Pneumococcal Polyvalent Vaccine","ValueMeaning":{"publicId":"3235526","version":"1","preferredName":"Conjugate Pneumococcal Polyvalent Vaccine","longName":"3235526","preferredDefinition":"A compound formed by the union of two entities or compounds.: An polyvalent vaccine used to prevent infection by the bacterium Streptococcus pneumoniae. Pneumococcal polyvalent vaccine contains highly purified capsular antigens from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae to ensure cross-protection. Following vaccination, protective capsular type-specific antibody levels typically develop by the third week; serotype-specific antibody levels generally decline after 5-10 years.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Conjugate","conceptCode":"C61533","definition":"A compound formed by the union of two entities or compounds.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pneumococcal Polyvalent Vaccine","conceptCode":"C1643","definition":"An polyvalent vaccine used to prevent infection by the bacterium Streptococcus pneumoniae. Pneumococcal polyvalent vaccine contains highly purified capsular antigens from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae to ensure cross-protection. Following vaccination, protective capsular type-specific antibody levels typically develop by the third week; serotype-specific antibody levels generally decline after 5-10 years.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A32B237B-1B17-0954-E040-BB89AD430712","latestVersionIndicator":"Yes","beginDate":"2011-05-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A32B237B-1B30-0954-E040-BB89AD430712","beginDate":"2011-05-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-13","modifiedBy":"ONEDATA","dateModified":"2011-05-13","deletedIndicator":"No"},{"value":"Unconjugated pneumococcal polysaccharide","valueDescription":"Negation Conjugate Pneumococcal Polyvalent Vaccine","ValueMeaning":{"publicId":"3235527","version":"1","preferredName":"Negation Conjugate Pneumococcal Polyvalent Vaccine","longName":"3235527","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: A compound formed by the union of two entities or compounds.: An polyvalent vaccine used to prevent infection by the bacterium Streptococcus pneumoniae. Pneumococcal polyvalent vaccine contains highly purified capsular antigens from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae to ensure cross-protection. Following vaccination, protective capsular type-specific antibody levels typically develop by the third week; serotype-specific antibody levels generally decline after 5-10 years.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Conjugate","conceptCode":"C61533","definition":"A compound formed by the union of two entities or compounds.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pneumococcal Polyvalent Vaccine","conceptCode":"C1643","definition":"An polyvalent vaccine used to prevent infection by the bacterium Streptococcus pneumoniae. Pneumococcal polyvalent vaccine contains highly purified capsular antigens from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae to ensure cross-protection. Following vaccination, protective capsular type-specific antibody levels typically develop by the third week; serotype-specific antibody levels generally decline after 5-10 years.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A32B237B-1B3E-0954-E040-BB89AD430712","latestVersionIndicator":"Yes","beginDate":"2011-05-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A32B237B-1B57-0954-E040-BB89AD430712","beginDate":"2011-05-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-13","modifiedBy":"ONEDATA","dateModified":"2011-05-13","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3235524","version":"1","preferredName":"Pneumococcal Polyvalent Vaccine Type","preferredDefinition":"An polyvalent vaccine used to prevent infection by the bacterium Streptococcus pneumoniae. Pneumococcal polyvalent vaccine contains highly purified capsular antigens from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae to ensure cross-protection. Following vaccination, protective capsular type-specific antibody levels typically develop by the third week; serotype-specific antibody levels generally decline after 5-10 years.:Type; a subdivision of a particular kind of thing.","longName":"C1643:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pneumococcal Polyvalent Vaccine","conceptCode":"C1643","definition":"An polyvalent vaccine used to prevent infection by the bacterium Streptococcus pneumoniae. Pneumococcal polyvalent vaccine contains highly purified capsular antigens from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae to ensure cross-protection. Following vaccination, protective capsular type-specific antibody levels typically develop by the third week; serotype-specific antibody levels generally decline after 5-10 years.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A32B237B-1AED-0954-E040-BB89AD430712","latestVersionIndicator":"Yes","beginDate":"2011-05-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-13","modifiedBy":"ONEDATA","dateModified":"2011-05-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A32B237B-1AFE-0954-E040-BB89AD430712","latestVersionIndicator":"Yes","beginDate":"2011-05-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-13","modifiedBy":"KUMMEROA","dateModified":"2021-03-30","changeDescription":". 2021-3-30 ak OK to release per WZ.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"3234637","version":"1","longName":"2131r2: Immune Deficiencies Post-HSCT Data","context":"NHLBI"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"What is the pneumococcal poly","type":"Preferred Question Text","description":"What is the pneumococcal polysaccharide type?","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A32C8E49-9886-F201-E040-BB89AD434459","latestVersionIndicator":"Yes","beginDate":"2011-05-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-13","modifiedBy":"KUMMEROA","dateModified":"2021-03-30","changeDescription":". 2021-3-30 ak OK to release per WZ. 2021-3-4 ak System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}